- Home
- AMSF vs ORKA Comparison
AMSF vs ORKA Comparison
Compare AMSF & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | ORKA |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.3M | 1.6B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMSF | ORKA |
|---|---|---|
| Price | $32.73 | $45.54 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $50.33 | ★ $57.25 |
| AVG Volume (30 Days) | 187.6K | ★ 562.0K |
| Earning Date | 04-28-2026 | 03-12-2026 |
| Dividend Yield | ★ 8.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $317,252,000.00 | N/A |
| Revenue This Year | $8.06 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | $13.35 | ★ N/A |
| Revenue Growth | ★ 2.66 | N/A |
| 52 Week Low | $32.00 | $5.49 |
| 52 Week High | $53.27 | $47.25 |
Technical Indicators
Market Signals| Indicator | AMSF | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 69.55 |
| Support Level | $32.08 | $26.02 |
| Resistance Level | $33.74 | N/A |
| Average True Range (ATR) | 0.71 | 3.21 |
| MACD | 0.11 | 0.73 |
| Stochastic Oscillator | 39.45 | 89.39 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.